Title:
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR study) View
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) View
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II/III
Title:
Association of Patient Activation with the Health-Related Quality of Life of Pancreatic Cancer Patients View
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center Open-Label Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR BV in pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph2 A+AVD +G-CSF or AOAD in CHL View
Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph1 CX-4945 Basal Cell Carcinoma View
Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)
Indication:
Skin Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
NeoAdj Chemo +/- Nivo/IDO1inh MIBC View
Description: A Phase 3 Randomized Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205 Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Thyroid Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Zanu in Ibrut/Acala intolerant B-Cell View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Zanu in Ibrut/Acala intolerant B-Cell View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1/2 CDK7 inhibitor HR+ BC View
Description: A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (CT7001_001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph 3 Sit+Nivo vs. Docetaxel NSCLC View
Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab Compared toDaratumumab SC in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4) View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1/2 AGEN1884 Adv Refractory cancer View
Description: A Phase 1/2 Open-Label Multicenter Study to Evaluate the Safety Pharmacokinetics andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)
Indication:
Liver Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph 1/1b TNBC Ovarian View
Description: (AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1 SEA-BCMA R/R MM View
Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph3b Venetoclax AML View
Description: A Phase 3b Single-Arm Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Anal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bone Mets
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Uterine Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vaginal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kaposi's Sarcoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kidney Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Liver Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Cervical Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
EAP BGB-3111 B-Cell Malig View
Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
Ph 3 Nivo vs. Plac Hepatocell Carc View
Description: A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CA209-9DX)
Indication:
Liver Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 3 NUC-1031+Cis vs Gem/Cis la/mBTC View
Description: A Phase III Open-Label Multi-Centre Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer (NuTide:121)
Indication:
Biliary Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 2 Nivo+Ipil Ipil mono or Caba CR mPC View
Description: A Phase 2 Trial of Nivolumab Plus Ipilimumab Ipilimumab Alone or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (CA209-650)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Biomarker DNA Defect Men Prostate View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
Ph 3 Irino Oxa Flu Leu Pac + GEM mPan View
Description: An open-label randomised multicentre phase III study of irinotecan liposome injection oxaliplatin 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (D-US-60010-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH2 MM Carf Poma & dexa (KPd) View
Description: An Open-label Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib Pomalidomide and Dexamethasone (KPd) (20180117)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
PH3 Ven+G vs FCR/BR in Fit untreated CLL View
Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Nivo +/- Doce mPC 7DX View
Description: A Phase 3 Randomized Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Tira atezo NSCL View
Description: A PHASE III RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB AN ANTI-TIGIT ANTIBODYIN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH3 Atezo Carbo Etopo +/- Tira SCL View
Description: A Phase III Randomized Double-Blind Placebo-controlled study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (Anti-Tigit Antibody) in patients with untreated extensive-stage small cell lung cancer (GO41767)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 Ublituximab+ Umbralisib+ Venetoc CLL View
Description: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
PH3 Neo/Adj Dura Stage 2/3 NSCL (AEGEAN) View
Description: A Phase III Double-blind Placebo-controlled Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) (D9106C00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Fruq + Placebo CC (FRESCO-2) View
Description: A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH3 Ate +Cabo Renal Carcinoma View
Description: A PHASE III MULTICENTER RANDOMIZED OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)
Indication:
Renal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH3 Dara/Len vs Len NDMM View
Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph2 m7824 triple neg BC View
Description: (MS200647_0020) A Phase II Multicenter Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH2 Brentux+CHP In Tx Naive PTCL View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Hematologic
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)
Indication:
Rectal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III